Abemaciclib + Endocrine Therapy Improves Survival in HR-Positive, HER2-Negative Early Breast Cancer

15.8 percent lower risk for death seen with abemaciclib-ET versus ET in intent-to-treat population
Senior woman having mammogram
Shutterstock
Medically Reviewed By:
Farrokh Sohrabi, M.D.
Published on
Updated on
Loading content, please wait...

Related Stories

No stories found.
logo
www.healthday.com